Twist Bioscience reports FY2022 revenue $203.6M (+54% YoY); guides FY2023 revenue $261-269M

Twist Bioscience Corp

2022-FY EPS reported -$4.04 revenue$203,565,000

FY2022 revenue $203.6M, up 54% YoY; net loss $217.9M ($4.04/share) vs $152.1M loss in FY2021.
Q4 FY2022 revenue $57.3M (up 51% YoY); net loss $51.1M ($0.91/share).
Full year orders $226M, up 42% YoY; shipped 558,000 genes vs 372,000 in FY2021.
FY2023 revenue guidance $261-269M; FY2024 target $350M.
Promoted Patrick Finn, Ph.D. to president and COO; partnered with Illumina and PacBio.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Twist Bioscience Corp reported fiscal year ended September 30, 2022 results: revenue $203.6 million, net income $217.9 million, EPS $4.04 per share. Guidance initiated.

Period: fiscal year ended September 30, 2022
Revenue: $203.6 million
Net income: $217.9 million
EPS: $4.04 per share
Guidance: initiated
Result: reported results

Exact text from the filing

FISCAL 2022 FINANCIAL RESULTS • Orders : Total orders received for fiscal 2022 were $226 million compared to $159.5 million for fiscal 2021. • Revenue : Total revenues for fiscal 2022 were $203.6 million compared to $132.3 million for fiscal 2021. • Cost of Revenues : Cost of revenues for fiscal 2022 was $119.3 million compared to $80.6 million for fiscal 2021. • Research and Development Expenses : Research and development expenses for fiscal 2022 were $120.3 million compared to $69.1 million for fiscal 2021. • Selling, General and Administrative Expenses: Selling, general and administrative expenses for fiscal 2022 were $212.9 million compared to $135.9 million for fiscal 2021. • Net Loss: Net loss attributable to common stockholders for fiscal 2022 was $217.9 million , or $4.04 per share, compared to $152.1 million , or $3.15 per share, for fiscal 2021.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Twist Bioscience Corp reported the fourth quarter of fiscal 2022 results: revenue $57.3 million, net income $51.1 million, EPS $0.91 per share. Guidance initiated.

Period: the fourth quarter of fiscal 2022
Revenue: $57.3 million
Net income: $51.1 million
EPS: $0.91 per share
Guidance: initiated
Result: reported results

Exact text from the filing

FISCAL 2022 FOURTH QUARTER FINANCIAL RESULTS • Orders: Total orders received for the fourth quarter of fiscal 2022 were $62.1 million compared to $45.2 million for the same period of fiscal 2021 . • Revenue: Total revenues for the fourth quarter of fiscal 2022 were $57.3 million compared to $38.0 million for the same period of fiscal 2021 . • Cost of Revenues: Cost of revenues for the fourth quarter of fiscal 2022 was $31.6 million compared to $22.5 million for the same period of fiscal 2021 . • Research and Development Expenses: Research and development expenses for the fourth quarter of fiscal 2022 were $29.6 million compared to $19.4 million for the same period of fiscal 2021 . • Selling, General and Administrative Expenses: Selling, general and administrative expenses for the fourth quarter of fiscal 2022 were $54.2 million compared to $38.2 million for the same period of fiscal 2021 . • Net Loss: Net loss attributable to common stockholders for the fourth quarter of fiscal 2022 wa

View on SEC.gov

Browse all earnings releases →

Twist Bioscience Corp filing history →

Source: SEC EDGAR

accession 0001628280-22-030393

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.